Pharma marketers hesitate on AI for regulatory filings - eMarketer

# Pharma Marketers Voice Concerns Over AI Reliability in Regulatory Processes The pharmaceutical marketing industry is approaching AI implementation with notable caution, according to recent research that should serve as a wake-up call for businesses across sectors. **The Reality Check on AI Adoption** A Momentum survey conducted between July and October 2025 revealed significant skepticism among pharma marketing and review professionals regarding AI-driven marketing tools. The study, which polled 40 industry experts, found that 40% identified AI hallucinations—instances where artificial intelligence generates false or misleading information—as their primary concern. This skepticism is particularly pronounced when considering AI's role in creating regulatory filings, where accuracy isn't just preferred; it's legally mandated. **What This Means for Your Marketing Strategy** For businesses exploring AI-driven marketing solutions, the pharmaceutical industry's cautious approach offers valuable lessons. While AI promises efficiency and innovation, the technology's tendency to produce inaccurate outputs poses real risks, especially in regulated industries. Success requires balancing automation benefits with robust human oversight and verification processes. **Key Takeaway** Organizations implementing AI marketing tools must prioritize accuracy validation systems and maintain human review protocols. The pharmaceutical sector's measured approach demonstrates that responsible AI adoption means acknowledging current limitations while preparing for future capabilities. Don't let enthusiasm for innovation overshadow the fundamental need for reliability and compliance. #AIMarketing #PharmaceuticalMarketing #AIStrategy #MarketingTechnology

# Pharma Marketers Voice Concerns Over AI Reliability in Regulatory Processes

The pharmaceutical marketing industry is approaching AI implementation with notable caution, according to recent research that should serve as a wake-up call for businesses across sectors.

**The Reality Check on AI Adoption**

A Momentum survey conducted between July and October 2025 revealed significant skepticism among pharma marketing and review professionals regarding AI-driven marketing tools. The study, which polled 40 industry experts, found that 40% identified AI hallucinations—instances where artificial intelligence generates false or misleading information—as their primary concern. This skepticism is particularly pronounced when considering AI's role in creating regulatory filings, where accuracy isn't just preferred; it's legally mandated.

**What This Means for Your Marketing Strategy**

For businesses exploring AI-driven marketing solutions, the pharmaceutical industry's cautious approach offers valuable lessons. While AI promises efficiency and innovation, the technology's tendency to produce inaccurate outputs poses real risks, especially in regulated industries. Success requires balancing automation benefits with robust human oversight and verification processes.

**Key Takeaway**

Organizations implementing AI marketing tools must prioritize accuracy validation systems and maintain human review protocols. The pharmaceutical sector's measured approach demonstrates that responsible AI adoption means acknowledging current limitations while preparing for future capabilities. Don't let enthusiasm for innovation overshadow the fundamental need for reliability and compliance.

#AIMarketing #PharmaceuticalMarketing #AIStrategy #MarketingTechnology

Original Source

Momentum conducted an online survey of 40 pharma marketing and review professionals from July to October 2025. 40% said AI hallucinations were their ...